Every reference with a DOI in the deposited reference list resolved to a known
work in Crossref or DataCite at the dated check, and none carried a retraction,
withdrawal, or removal notice.
The 41 checked references that resolve
resolves10.1002/pmic.200800633Proteomic analysis of multidrug‐resistance mechanisms in adriamycin‐resistant variants of DLKP, a squamous lung cancer cell line
resolves10.1002/pmic.200800626Proteomic analysis of doxorubicin‐induced changes in the proteome of HepG2cells combining 2‐D DIGE and LC‐MS/MS approaches
resolves10.1016/S0959-8049(97)00338-9Low toxicity and high antitumour activity of Daunomycin by conjugation to an immunopotential amphoteric branched polypeptide
resolves10.1016/S0960-894X(99)00678-2Structure–activity relationships of carboxymethylpullulan-peptide-doxorubicin conjugates—systematic modification of peptide spacers
resolves10.1002/bip.360220168Specific and nonspecific macromolecule–drug conjugates for the improvement of cancer chemotherapy
resolves10.1016/S0304-3835(77)96407-2Steric influence of the orientation of the primary amino group at position 3 of the sugar moiety of anthracycline antibiotics in DNA binding properties
resolves10.1016/j.bmc.2006.02.007Correlation of the acid-sensitivity of polyethylene glycol daunorubicin conjugates with their in vitro antiproliferative activity
resolves10.1021/jm00278a032Antitumor activity of some derivatives of daunorubicin at the amino and methyl ketone functions
resolves10.1016/j.bmc.2005.02.040Improved synthesis of daunomycin conjugates with triplex-forming oligonucleotides. The polypurine tract of HIV-1 as a target
resolves10.1021/jm0606591Improved Therapeutic Efficacy of Doxorubicin through Conjugation with a Novel Peptide Drug Delivery Technology (Vectocell)
resolves10.1124/mol.57.4.679New Advances in the Transport of Doxorubicin through the Blood-Brain Barrier by a Peptide Vector-Mediated Strategy
resolves10.1002/bip.21264New daunomycin–oligoarginine conjugates: Synthesis, characterization, and effect on human leukemia and human hepatoma cells
resolves10.1007/0-306-46817-4_16Development of Clinical Trial of E1A Gene Therapy Targeting HER-2/neu-overexpressing Breast and Ovarian Cancer
resolves10.1016/S1368-7646(03)00024-4The interface between ErbB and non-ErbB receptors in tumor invasion: clinical implications and opportunities for target discovery
resolves10.1096/fj.02-0280fjeIdentification of novel carrier peptides for the specific delivery of therapeutics into cancer cells
resolves10.1093/jnci/djq315Effect of Multikinase Inhibitors on Caspase-Independent Cell Death and DNA Damage in HER2-Overexpressing Breast Cancer Cells
resolves10.1002/ijc.24580Increased expression of ErbB‐2 in liver is associated with hepatitis B × antigen and shorter survival in patients with liver cancer
resolves10.1021/bi00260a005Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on the interaction of daunomycin with deoxyribonucleic acid
resolves10.1016/0022-2836(74)90031-XTheoretical aspects of DNA-protein interactions: Co-operative and non-co-operative binding of large ligands to a one-dimensional homogeneous lattice
resolves10.1038/270347a0Continuous growth and differentiation of human myeloid leukaemic cells in suspension culture
resolves10.1016/j.bbrc.2010.01.055The pan-ErbB receptor tyrosine kinase inhibitor canertinib induces ErbB-independent apoptosis in human leukemia (HL-60 and U-937) cells
The 9 references without a DOI — listed, not checked
no DOI — not checkedref1/cit1
no DOI — not checkedCancer Management: A Multidisciplinary Approach
no DOI — not checkedref4/cit4
no DOI — not checkedref7/cit7
no DOI — not checkedref10/cit10
no DOI — not checkedref15/cit15
no DOI — not checkedref17/cit17
no DOI — not checkedref29/cit29
no DOI — not checkedref44/cit44
checked 2026-07-23 — re-checked daily as this page is visited;
titles and statuses come from Crossref and DataCite and are not part of the signed record
Both snippets point at the live badge image and link back to this page. The
badge re-renders from the daily check, so an embed never goes stale by more than a day of visits.